Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coagulation factor XIII B chain is a plasma protein encoded by the F13B gene that forms part of the factor XIII heterotetramer (A2B2), essential for the final steps of the blood clotting cascade.[1][2][3][4][5] The B chain acts as a regulatory and carrier subunit: it stabilizes the catalytic A subunits in circulation until activation by thrombin and calcium ions, at which point the B subunits dissociate, enabling the A subunits to cross-link fibrin and stabilize blood clots.[1][2][3][5] Deficiency of the B chain results in a rare bleeding disorder with impaired wound healing, and F13B is also implicated in other physiological functions such as angiogenesis, bone formation, and immune response.[1][2][3][5] While therapeutic targeting is not typical except for replacement in deficiency, it is a crucial molecule for hemostasis.[1][3][5]
Replacement therapy to restore clot stability and coagulation in deficiency
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coagulation factor XIII B chain (F13B).